These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

454 related items for PubMed ID: 18959605

  • 21. Injection of acidic or neutral insulin and pain: a single-center, prospective, controlled, noninterventional study in pediatric patients with type 1 diabetes mellitus.
    Karges B, Muche R, Riegger I, Moritz M, Heinze E, Debatin KM, Wabitsch M, Karges W.
    Clin Ther; 2006 Dec; 28(12):2094-101. PubMed ID: 17296465
    [Abstract] [Full Text] [Related]

  • 22. Comparison of incidence of acute myocardial infarction in patients with type 2 diabetes mellitus following initiation of neutral protamine Hagedorn insulin versus insulin glargine.
    Rhoads GG, Kosiborod M, Nesto RW, Fonseca VA, Lu SE, Zhang Q, Foody JM.
    Am J Cardiol; 2009 Oct 01; 104(7):910-6. PubMed ID: 19766755
    [Abstract] [Full Text] [Related]

  • 23. Comparison of the subcutaneous absorption of insulin glargine (Lantus) and NPH insulin in patients with Type 2 diabetes.
    Luzio SD, Beck P, Owens DR.
    Horm Metab Res; 2003 Jul 01; 35(7):434-8. PubMed ID: 12931275
    [Abstract] [Full Text] [Related]

  • 24. Patient-level meta-analysis of efficacy and hypoglycaemia in people with type 2 diabetes initiating insulin glargine 100U/mL or neutral protamine Hagedorn insulin analysed according to concomitant oral antidiabetes therapy.
    Owens DR, Traylor L, Mullins P, Landgraf W.
    Diabetes Res Clin Pract; 2017 Feb 01; 124():57-65. PubMed ID: 28092788
    [Abstract] [Full Text] [Related]

  • 25. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy.
    Fulcher GR, Gilbert RE, Yue DK.
    Intern Med J; 2005 Sep 01; 35(9):536-42. PubMed ID: 16105155
    [Abstract] [Full Text] [Related]

  • 26. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
    Hauner H, Kohlmann T, Landgraf W, Holle R, Pirk O, Scholten T.
    Dtsch Med Wochenschr; 2009 Jun 01; 134(23):1207-13. PubMed ID: 19472091
    [Abstract] [Full Text] [Related]

  • 27. Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort.
    Dornhorst A, Lüddeke HJ, Sreenan S, Koenen C, Hansen JB, Tsur A, Landstedt-Hallin L.
    Int J Clin Pract; 2007 Mar 01; 61(3):523-8. PubMed ID: 17313628
    [Abstract] [Full Text] [Related]

  • 28. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes.
    Raslová K, Bogoev M, Raz I, Leth G, Gall MA, Hâncu N.
    Diabetes Res Clin Pract; 2004 Nov 01; 66(2):193-201. PubMed ID: 15533587
    [Abstract] [Full Text] [Related]

  • 29. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes.
    Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T.
    Diabetes Obes Metab; 2007 May 01; 9(3):290-9. PubMed ID: 17391154
    [Abstract] [Full Text] [Related]

  • 30. Insulin glargine (Lantus).
    Owens DR, Griffiths S.
    Int J Clin Pract; 2002 May 01; 56(6):460-6. PubMed ID: 12166545
    [Abstract] [Full Text] [Related]

  • 31. A randomized, controlled trial comparing twice-a-day insulin glargine mixed with rapid-acting insulin analogs versus standard neutral protamine Hagedorn (NPH) therapy in newly diagnosed type 1 diabetes.
    Hassan K, Rodriguez LM, Johnson SE, Tadlock S, Heptulla RA.
    Pediatrics; 2008 Mar 01; 121(3):e466-72. PubMed ID: 18299307
    [Abstract] [Full Text] [Related]

  • 32. Early retinopathy progression in four randomized trials comparing insulin glargine and NPH [corrected] insulin.
    Davis MD, Beck RW, Home PD, Sandow J, Ferris FL.
    Exp Clin Endocrinol Diabetes; 2007 Apr 01; 115(4):240-3. PubMed ID: 17479440
    [Abstract] [Full Text] [Related]

  • 33. Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study.
    Wenying Y, Benroubi M, Borzi V, Gumprecht J, Kawamori R, Shaban J, Shah S, Shestakova M, Ligthelm R, Valensi P, IMPROVE Study Group Expert Panel.
    Curr Med Res Opin; 2009 Nov 01; 25(11):2643-54. PubMed ID: 19751116
    [Abstract] [Full Text] [Related]

  • 34. Insulin glargine: a long-acting insulin for diabetes mellitus.
    Garces K.
    Issues Emerg Health Technol; 2003 Nov 01; (52):1-4. PubMed ID: 14626260
    [Abstract] [Full Text] [Related]

  • 35. Long-term glycaemic control with insulin glargine in Type 2 diabetes.
    Kacerovsky-Bielesz G, Dressler A, Freunscht R.
    Diabetes Res Clin Pract; 2006 Feb 01; 71(2):184-91. PubMed ID: 16112241
    [Abstract] [Full Text] [Related]

  • 36. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients.
    Riddle MC, Rosenstock J, Gerich J, Insulin Glargine 4002 Study Investigators.
    Diabetes Care; 2003 Nov 01; 26(11):3080-6. PubMed ID: 14578243
    [Abstract] [Full Text] [Related]

  • 37. Resource utilisation and costs in patients with type 2 diabetes mellitus treated with insulin glargine or conventional basal insulin under real-world conditions in Germany: LIVE-SPP study.
    Schöffski O, Breitscheidel L, Benter U, Dippel FW, Müller M, Volk M, Pfohl M.
    J Med Econ; 2008 Nov 01; 11(4):695-712. PubMed ID: 19450076
    [Abstract] [Full Text] [Related]

  • 38. Refining basal insulin therapy: what have we learned in the age of analogues?
    Devries JH, Nattrass M, Pieber TR.
    Diabetes Metab Res Rev; 2007 Sep 01; 23(6):441-54. PubMed ID: 17668418
    [Abstract] [Full Text] [Related]

  • 39. Insulin therapy in type 2 diabetes: what is the evidence?
    van Avendonk MJ, Rutten GE.
    Diabetes Obes Metab; 2009 May 01; 11(5):415-32. PubMed ID: 19175375
    [Abstract] [Full Text] [Related]

  • 40. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial.
    Fritsche A, Schweitzer MA, Häring HU, 4001 Study Group.
    Ann Intern Med; 2003 Jun 17; 138(12):952-9. PubMed ID: 12809451
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.